Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.30 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.30 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.30 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11343544 | 0.79 | TDP1 (0.38) | CYP3A4TSHRALDH1A1MAOBCYP1A2 | |
| SCHEMBL5175336 | 0.78 | MAOB (0.35) | ALDH1A1MAPK1MAOBCYP1A2CYP2A6 | |
| SCHEMBL7653242 | 0.76 | MAOB (0.34) | ALDH1A1MAPK1MAOBCYP1A2CYP2A6 | |
| Lithium Ion SCHEMBL18242119 | 0.75 | ALDH1A1 (0.38) | CYP3A4TSHRALDH1A1MAOBCYP1A2 | |
| SCHEMBL10664205 | 0.75 | TDP1 (0.38) | CYP3A4TSHRALDH1A1CYP1A2CYP2A6 | |
| Potassium Ion SCHEMBL18242492 | 0.75 | ALDH1A1 (0.38) | CYP3A4TSHRALDH1A1MAOBCYP1A2 | |
| SCHEMBL8815943 | 0.72 | HTT (0.40) | TSHRALDH1A1CA12CA1CA2 | |
| SCHEMBL8815947 | 0.72 | CA2 (0.47) | CA1CA2 | |
| Lithium Ion SCHEMBL18242121 | 0.71 | TDP1 (0.38) | CYP3A4TSHRALDH1A1CYP1A2CYP2A6 | |
| Potassium Ion SCHEMBL18242494 | 0.71 | TDP1 (0.38) | CYP3A4TSHRALDH1A1CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1097141-B1 | IMIDAZOLE DERIVATIVES WITH BIPHENYLSULFONYL SUBSTITUTION, METHOD FOR PREPARING THEM AND THEIR USE AS A DRUG OR DIAGNOSTIC AGENT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-05-23 | — | — | EP | disclosed |
| EP-1097140-B1 | BIPHENYLSULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS A DRUG OR DIAGNOSTIC AGENT AND DRUG CONTAINING THEM | AVENTIS PHARMA GMBH (DE) | 2004-03-03 | — | — | EP | disclosed |
| EP-1053224-B1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2002-08-21 | — | — | EP | disclosed |
| US-6372917-B1 | INHIBIT CELLULAR SODIUM ION-DEPENDENT CHLORIDE ION/BICARBONATE-EXCHANGE MECHANISM OR SODIUM/BICARBONATE SYMPORTER; TREATMENT OF ALL ACUTE OR CHRONIC DAMAGE CAUSED BY ISCHEMIA OR ILLNESSES INDUCED THEREBY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-16 | — | — | US | disclosed |
| US-6369236-B1 | DRUG FOR MEDICAL DIAGNOSIS ANTIARRHYTHMIC PROPRIETIES AND CONTAIN A CARDIOPROTECTIVE COMPOUND. THEY CAN PREVENTIVELY INHIBIT OR STRONGLY REDUCE PATHOPHYSIOLOGIC PROCESSES UPON OCCURRENCE OF ISCHEMIC INJURIES, ESPECIALLY ISCHEMIC CARDIAC | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| US-6369069-B1 | CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| EP-1097140-A2 | BIPHENYLSULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS A DRUG OR DIAGNOSTIC AGENT AND DRUG CONTAINING THEM | Aventis Pharma Deutschland GmbH (DE) | 2001-05-09 | — | — | EP | disclosed |
| EP-1097141-A1 | IMIDAZOLE DERIVATIVES WITH BIPHENYLSULFONYL SUBSTITUTION, METHOD FOR PREPARING THEM AND THEIR USE AS A DRUG OR DIAGNOSTIC AGENT | Aventis Pharma Deutschland GmbH (DE) | 2001-05-09 | — | — | EP | disclosed |
| EP-1053224-A1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | Aventis Pharma Deutschland GmbH (DE) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000003994-A2 | BIPHENYLSULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS A DRUG OR DIAGNOSTIC AGENT AND DRUG CONTAINING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
| WO-2000003996-A1 | IMIDAZOLE DERIVATIVES WITH BIPHENYLSULFONYL SUBSTITUTION, METHOD FOR PREPARING THEM AND THEIR USE AS A DRUG OR DIAGNOSTIC AGENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999040064-A1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-08-12 | — | — | WO | disclosed |